Clinical Trial News and Research

RSS

Biosimilar medications could cut spending on biologics in the U.S. by $44 billion

Introducing competing "biosimilar" versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the United States by $44 billion over the next decade, according to new analysis from the RAND Corporation.

6 Nov 2014

Asthma patients using behavioral therapy can improve lung health over the long-term

Asthma patients taught to habitually resist the urge to take deep breaths when experiencing symptoms were rewarded with fewer symptoms and healthier lung function, according to a new study from Southern Methodist University, Dallas.

6 Nov 2014

Non-injectable vaccine may provide long-term protection against deadly Ebola virus

A potentially breathable, respiratory vaccine in development has been shown to provide long-term protection for non-human primates against the deadly Ebola virus, as reported this week in the online edition of the journal Molecular Pharmaceutics.

5 Nov 2014

Common drug could become the future standard of care for HE patients

A common drug used to clean a person's bowels before a colonoscopy could become the future standard of care for patients with acute hepatic encephalopathy (HE), a mental disorientation problem that affects up to one in two cirrhosis patients.

4 Nov 2014

Study: Tonsil removal for children with sleep apnea decreases asthma severity

Surgical removal of the tonsils and adenoids in children suffering from sleep apnea is associated with decreased asthma severity, according to the first large study of the connection, published in the journal PLOS Medicine.

4 Nov 2014

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca and Pharmacyclics, Inc. today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors.

4 Nov 2014

Ruthigen enrolls first patient in Phase 1/2 clinical trial of RUT58-60

Ruthigen, Inc., announced today enrollment of the first patient in a Randomized, Double-Blind Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of its lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery.

4 Nov 2014

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2014.

4 Nov 2014

Inventiva’s IVA337 receives EMA COMP positive opinion on orphan drug designation for SSc treatment

Inventiva, a drug discovery company that focuses on therapeutic approaches involving transcription factors and epigenetic targets, today announces that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has given a positive opinion on the designation of IVA337 as an orphan medicinal product.

4 Nov 2014

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

Merck Sharp & Dohme Ltd. MSD (known as Merck & Co., Inc. in the United States and Canada), today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection.

4 Nov 2014

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs.

4 Nov 2014

Nasal vaccine shows promise against Ebola virus

A nasal vaccine in development by researchers at The University of Texas at Austin has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Results from a small pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long-lasting, which could have significant global implications in controlling future outbreaks.

4 Nov 2014

Epicure project: an interview with Frédéric Cren

Epicure is a project led by Inventiva and Institut Curie that aims to deliver pre-clinical candidates on two novel epigenetic targets that have been selected due to their potential to activate immune responses against cancer cells. In addition one of these two targets has potential in respiratory indications such as asthma or COPD.

3 Nov 2014

APBI with proton therapy less costly than other traditional treatments for early stage breast cancer

In terms of duration of treatment and cost, patients with early stage breast cancer may benefit from accelerated partial breast irradiation (APBI) with proton therapy versus whole breast irradiation (WBI), according to new research from The University of Texas MD Anderson Proton Therapy Center.

3 Nov 2014

LAMA/LABA combination better than monotherapy for severe COPD

Combination treatment with umeclidinium bromide and vilanterol offers clinically meaningful improvements over tiotropium monotherapy for patients with moderate-to-very severe chronic obstructive pulmonary disease, study data show.

31 Oct 2014

Data reveals sustained local control for early stage lung cancer patients who receive SBRT

Analysis of data from an institutional patient registry on stereotactic body radiotherapy (SBRT) indicates excellent long-term, local control, 79 percent of tumors, for medically inoperable, early stage lung cancer patients treated with SBRT from 2003 to 2012, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.

31 Oct 2014

Dosing of antiretroviral medication to prevent HIV infection differs by sex

A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex.

31 Oct 2014

FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily SAVAYSA (edoxaban) 60 mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF).

30 Oct 2014

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia.

30 Oct 2014

Auxilium Pharmaceuticals reports total revenues of $109.6 million for Q3 2014

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the third quarter ending September 30, 2014.

30 Oct 2014

Clinical Trial News and Research

Biosimilar medications could cut spending on biologics in the U.S. by $44 billion

Asthma patients using behavioral therapy can improve lung health over the long-term

Non-injectable vaccine may provide long-term protection against deadly Ebola virus

Common drug could become the future standard of care for HE patients

Study: Tonsil removal for children with sleep apnea decreases asthma severity

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

Ruthigen enrolls first patient in Phase 1/2 clinical trial of RUT58-60

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Inventiva’s IVA337 receives EMA COMP positive opinion on orphan drug designation for SSc treatment

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

Nasal vaccine shows promise against Ebola virus

Epicure project: an interview with Frédéric Cren

APBI with proton therapy less costly than other traditional treatments for early stage breast cancer

LAMA/LABA combination better than monotherapy for severe COPD

Data reveals sustained local control for early stage lung cancer patients who receive SBRT

Dosing of antiretroviral medication to prevent HIV infection differs by sex

FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Auxilium Pharmaceuticals reports total revenues of $109.6 million for Q3 2014

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer